WO2004072025A3 - N-arylheterocycles substitues, procede de production et utilisation de ces derniers en tant que medicaments - Google Patents

N-arylheterocycles substitues, procede de production et utilisation de ces derniers en tant que medicaments Download PDF

Info

Publication number
WO2004072025A3
WO2004072025A3 PCT/EP2004/001342 EP2004001342W WO2004072025A3 WO 2004072025 A3 WO2004072025 A3 WO 2004072025A3 EP 2004001342 W EP2004001342 W EP 2004001342W WO 2004072025 A3 WO2004072025 A3 WO 2004072025A3
Authority
WO
WIPO (PCT)
Prior art keywords
arylheterocycles
production
medicaments
substituted
physiologically
Prior art date
Application number
PCT/EP2004/001342
Other languages
German (de)
English (en)
Other versions
WO2004072025A2 (fr
Inventor
Lothar Schwink
Siegfried Stengelin
Matthias Gossel
Thomas Boehme
Gerhard Hessler
Petra Stahl
Dirk Gretzke
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32841665&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004072025(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to NZ541823A priority Critical patent/NZ541823A/en
Priority to JP2006501827A priority patent/JP2006517563A/ja
Priority to CA002516118A priority patent/CA2516118A1/fr
Priority to AU2004212145A priority patent/AU2004212145B2/en
Priority to BRPI0407504-8A priority patent/BRPI0407504A/pt
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Priority to EP04710808A priority patent/EP1597228A2/fr
Priority to YUP-2005/0666A priority patent/RS20050666A/sr
Priority to MXPA05008449A priority patent/MXPA05008449A/es
Publication of WO2004072025A2 publication Critical patent/WO2004072025A2/fr
Publication of WO2004072025A3 publication Critical patent/WO2004072025A3/fr
Priority to TNP2005000194A priority patent/TNSN05194A1/en
Priority to HR20050710A priority patent/HRP20050710A2/xx
Priority to NO20054220A priority patent/NO20054220L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne des N-arylhétérocycles substitués ainsi que leurs sels physiologiquement acceptables et dérivés physiologiquement fonctionnels. Cette invention concerne également des composés de formule (I), dans laquelle les restes ont les significations indiquées, leurs N-oxydes, leurs sels physiologiquement acceptables ainsi qu'un procédé de production desdits composés. Ces composés peuvent être utilisés p. ex. en tant qu'anorexigènes.
PCT/EP2004/001342 2003-02-14 2004-02-13 N-arylheterocycles substitues, procede de production et utilisation de ces derniers en tant que medicaments WO2004072025A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MXPA05008449A MXPA05008449A (es) 2003-02-14 2004-02-13 N-arilheterociclos sustituidos, procedimientos para su preparacion, y su empleo como medicamentos.
YUP-2005/0666A RS20050666A (en) 2003-02-14 2004-02-13 Substituted n- arylheterocycles, method for production and use thereof as medicaments
CA002516118A CA2516118A1 (fr) 2003-02-14 2004-02-13 N-arylheterocycles substitues, procede de production et utilisation de ces derniers en tant que medicaments
AU2004212145A AU2004212145B2 (en) 2003-02-14 2004-02-13 Substituted N-arylheterocycles, method for production and use thereof as medicaments
BRPI0407504-8A BRPI0407504A (pt) 2003-02-14 2004-02-13 heterociclos n-arila substituìdo, processo para sua preparação e uso dos mesmos como medicamentos
NZ541823A NZ541823A (en) 2003-02-14 2004-02-13 Substituted N-aryl heterocycles, method for production and uses thereof as medicaments
EP04710808A EP1597228A2 (fr) 2003-02-14 2004-02-13 N-arylheterocycles substitues, procede de production et utilisation de ces derniers en tant que medicaments
JP2006501827A JP2006517563A (ja) 2003-02-14 2004-02-13 置換ｎ−アリール複素環化合物、その製造方法およびその医薬としての使用
HR20050710A HRP20050710A2 (en) 2003-02-14 2005-08-12 Substituted n-arylheterocycles, method for production and use thereof as medicaments
TNP2005000194A TNSN05194A1 (en) 2003-02-14 2005-08-12 Substituted n-arylheterocycles, method for production and use thereof as medicaments
NO20054220A NO20054220L (no) 2003-02-14 2005-09-12 Substituerte N-arylheterocykler, fremgangsmate for fremstilling derav og deres anvendelse som legemiddel

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10306250.5 2003-02-14
DE10306250A DE10306250A1 (de) 2003-02-14 2003-02-14 Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Publications (2)

Publication Number Publication Date
WO2004072025A2 WO2004072025A2 (fr) 2004-08-26
WO2004072025A3 true WO2004072025A3 (fr) 2004-12-23

Family

ID=32841665

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/001342 WO2004072025A2 (fr) 2003-02-14 2004-02-13 N-arylheterocycles substitues, procede de production et utilisation de ces derniers en tant que medicaments

Country Status (29)

Country Link
EP (1) EP1597228A2 (fr)
JP (1) JP2006517563A (fr)
KR (1) KR20050101215A (fr)
CN (1) CN100506792C (fr)
AR (1) AR044496A1 (fr)
AU (1) AU2004212145B2 (fr)
BR (1) BRPI0407504A (fr)
CA (1) CA2516118A1 (fr)
CO (1) CO5690548A2 (fr)
DE (1) DE10306250A1 (fr)
EC (1) ECSP055967A (fr)
HR (1) HRP20050710A2 (fr)
MA (1) MA27735A1 (fr)
MX (1) MXPA05008449A (fr)
MY (1) MY139102A (fr)
NO (1) NO20054220L (fr)
NZ (1) NZ541823A (fr)
OA (1) OA13027A (fr)
PA (1) PA8595901A1 (fr)
PE (1) PE20040952A1 (fr)
PL (1) PL378065A1 (fr)
RS (1) RS20050666A (fr)
RU (1) RU2005128551A (fr)
TN (1) TNSN05194A1 (fr)
TW (1) TW200510297A (fr)
UA (1) UA86760C2 (fr)
UY (1) UY28186A1 (fr)
WO (1) WO2004072025A2 (fr)
ZA (1) ZA200506369B (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US8716480B2 (en) 2009-05-12 2014-05-06 Janssen Pharmaceuticals, Inc. 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
US8748621B2 (en) 2007-09-14 2014-06-10 Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
US8785486B2 (en) 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8841323B2 (en) 2006-03-15 2014-09-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US8906939B2 (en) 2007-03-07 2014-12-09 Janssen Pharmaceuticals, Inc. 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
JP4939220B2 (ja) 2003-05-15 2012-05-23 アークル インコーポレイテッド ｐ３８の阻害物質としてのイミダゾチアゾール類およびイミダゾオキサゾール誘導体
NZ544009A (en) 2003-07-24 2009-07-31 Euro Celtique Sa Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
PL1867644T3 (pl) * 2003-07-24 2009-10-30 Euro Celtique Sa Związki heteroarylo-tetrahydropiperydylowe przydatne w leczeniu lub zapobieganiu bólu
EP2426120A1 (fr) * 2003-08-18 2012-03-07 Fujifilm Finechemicals Co., Ltd. Pyridyl-tétrahydropyridines et pyridyl-pipéridines et procédé de leur fabrication
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
DE10360745A1 (de) * 2003-12-23 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
DE102004003812A1 (de) * 2004-01-25 2005-08-11 Aventis Pharma Deutschland Gmbh Arylsubstituierte Heterozyklen, Verfahren ihrer Herstellung und ihre Verwendung als Arzneimittel
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
US7829560B2 (en) 2004-07-08 2010-11-09 Arqule, Inc. 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
WO2006022442A1 (fr) * 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. Nouveaux derives d’amides heterocycliques ayant une activite d’inhibition de la dihydroorotate deshydrogenase
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
JP5043668B2 (ja) * 2004-09-20 2012-10-10 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
WO2006038680A1 (fr) * 2004-10-01 2006-04-13 Banyu Pharmaceutical Co.,Ltd Composé hétérocyclique azoté substitué en 2 par un groupement arylcarboxamide
CN101094846A (zh) 2004-10-18 2007-12-26 伊莱利利公司 用作mglur3受体拮抗剂的1－(杂)芳基－3－氨基－吡咯烷衍生物
EP2258704A1 (fr) 2004-10-19 2010-12-08 ArQule, Inc. Synthese d'inhibiteurs d'imidazo-oxazole et d'imidazothiazole de la map kinase p38
DE102004051277A1 (de) * 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
US8084492B2 (en) * 2004-11-19 2011-12-27 The New Industry Research Organization Benzofuran compound and pharmaceutical composition containing the same
RS56194B1 (sr) 2004-12-30 2017-11-30 Janssen Pharmaceutica Nv Derivativi fenilamida 4-(benzil)-piperazin-1-karboksilne kiseline i slična jedinjenja kao modulatori hidrolaze amida masnih kiselina (faah) za lečenje anksioznosti, bola i ostalih stanja
TWI444187B (zh) 2005-01-25 2014-07-11 Synta Pharmaceuticals Corp 用於炎症及免疫相關用途之噻吩化合物
ATE429428T1 (de) 2005-09-30 2009-05-15 Hoffmann La Roche Indanderivate als antagonisten des mch-rezeptors
CA2641744C (fr) 2006-02-10 2012-09-25 Transtech Pharma, Inc. Derives, compositions de benzazole et procedes d'utilisation en tant qu'inhibiteurs de la kinase aurora
JP2009526794A (ja) * 2006-02-15 2009-07-23 サノフィ−アベンティス 新規なアミノアルコール置換アリールチエノピリミジノン、それらの製造方法及び薬剤としてそれらの使用
KR20080095879A (ko) * 2006-02-15 2008-10-29 사노피-아벤티스 신규 아자사이클릴-치환된 아릴티에노피리미디논, 이의 제조 방법 및 이의 약물로서의 용도
CN101426774B (zh) * 2006-04-19 2012-04-25 安斯泰来制药有限公司 唑类甲酰胺衍生物
PL2010528T3 (pl) 2006-04-19 2018-03-30 Novartis Ag 6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r
UA93548C2 (uk) 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
WO2007133562A2 (fr) 2006-05-08 2007-11-22 Ariad Pharmaceuticals, Inc. Composés d'hétéroaryle monocyclique
MX2008014289A (es) 2006-05-08 2008-11-26 Ariad Pharma Inc Compuestos heteroarilicos acetilenicos.
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
BRPI0719122A2 (pt) * 2006-08-24 2013-12-10 Novartis Ag Compostos orgânicos
KR20090064447A (ko) 2006-09-11 2009-06-18 글락소 그룹 리미티드 모노아민 재흡수 억제제로서의 아자바이시클릭 화합물
US20080076770A1 (en) * 2006-09-25 2008-03-27 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
PE20080888A1 (es) * 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
ES2449482T3 (es) * 2007-01-09 2014-03-19 Amgen Inc. Derivados de bis-aril-amida útiles para el tratamiento de cáncer
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
CA2687912C (fr) 2007-06-08 2015-11-03 Janssen Pharmaceutica N.V. Derives de piperidine/piperazine
US8633197B2 (en) 2007-06-08 2014-01-21 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
CA2687754C (fr) * 2007-06-08 2015-12-08 Janssen Pharmaceutica N.V. Derives de piperidine/piperazine pour utilisation en tant qu'inhibiteurs de dgat
TWI452044B (zh) * 2007-06-15 2014-09-11 Mitsubishi Tanabe Pharma Corp 嗎啉衍生物
TW200918521A (en) * 2007-08-31 2009-05-01 Astrazeneca Ab Heterocyclic amides and methods of use thereof
RS52221B (en) * 2007-10-17 2012-10-31 Sanofi N-PHENYL-BIPYROLIDUM UREA SUBSTITUTED AND THE THERAPEUTIC USES thereof
RU2477720C2 (ru) * 2007-10-17 2013-03-20 Санофи-Авентис Замещенные n-фенилбипирролидинкарбоксамиды и их применение в лечебных целях
MY150210A (en) * 2007-10-17 2013-12-13 Sanofi Aventis Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators
CN101903339B (zh) * 2007-10-17 2012-06-27 赛诺菲-安万特 取代的n-苯基-联吡咯烷羧酰胺及其治疗用途
CA2703106C (fr) 2007-10-24 2015-12-01 Astellas Pharma Inc. Derives d'azolecarboxamide comme inhibiteurs de trka
EP2070925A1 (fr) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Nouveaux dérivés de 2-thiazol-4-amides d'acide carboxylique substitués, leur fabrication et leur utilisation en tant que médicament
EP2070916A1 (fr) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Dérivés de 2-aryl-thiazol-4-amides d'acide carboxylique, leur fabrication et leur utilisation en tant que médicament
EP2070924A1 (fr) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Nouveaux dérivés de 2-hetarylthiazol-4-amides d'acide carboxylique, leur fabrication et leur utilisation en tant que médicament
RU2364597C1 (ru) * 2007-12-14 2009-08-20 Андрей Александрович Иващенко ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
UY31863A (es) 2008-06-05 2010-01-05 Janssen Pharmaceutica Nv Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
WO2010003624A2 (fr) 2008-07-09 2010-01-14 Sanofi-Aventis Composés hétérocycliques, leurs procédés de préparation, médicaments comprenant lesdits composés et leur utilisation
BRPI0918055A2 (pt) 2008-09-02 2015-12-01 Addex Pharmaceuticals Sa derivados de 3-azabiciclo[3,1,0]hexila como moduladores de receptores metabotrópicos de glutamato.
US20110318266A1 (en) * 2008-09-16 2011-12-29 Mccauley John A Phthalimide derivative metabotropic glutamate r4 ligands
JP2012006837A (ja) * 2008-09-30 2012-01-12 Mochida Pharmaceut Co Ltd ２−インドールアクリルアミド類縁体
CA2738849C (fr) 2008-10-16 2016-06-28 Addex Pharma S.A. Derives d'indole et de benzomorpholine en tant que modulateurs des recepteurs metabotropiques du glutamate
WO2010056311A1 (fr) 2008-11-12 2010-05-20 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines et dérivés utiles comme inhibiteurs de kinases
AR074466A1 (es) * 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
WO2010101246A1 (fr) * 2009-03-05 2010-09-10 塩野義製薬株式会社 Dérivés de la pipéridine et de la pyrrolidine dotés d'un antagonisme pour les récepteurs npy y5
EP2404896A1 (fr) 2009-03-05 2012-01-11 Shionogi&Co., Ltd. Dérivé de cyclohexane présentant un antagonisme du récepteur npy y5
EP2470552B1 (fr) 2009-08-26 2013-11-13 Sanofi Nouveaux hydrates de fluoroglycoside hétéroaromatiques cristallins, produits pharmaceutiques comprenant ces composés et leur utilisation
WO2011060026A1 (fr) 2009-11-12 2011-05-19 Jansen Pharmaceutica Nv Dérivé de pipérazine-carboxamide utile en tant que modulateur de la faah (fatty acid amide hydrolase)
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
EP2569294B1 (fr) * 2010-05-11 2015-03-11 Sanofi Bipyrrolidine carboxamides n-heteroaromatiques, leur preparation et usage therapeutique
WO2011143148A1 (fr) * 2010-05-11 2011-11-17 Sanofi Bipyrrolidines n-hétéroaryl spirolactame substituées, procédé de préparation et usage thérapeutique associés
JP5968307B2 (ja) * 2010-05-11 2016-08-10 サノフイ 置換フェニルシクロアルキルピロリジン（ピペリジン）スピロラクタム類及びアミド類、それらの製造及び治療的使用
UY33469A (es) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
EP2683698B1 (fr) 2011-03-08 2017-10-04 Sanofi Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
WO2012120057A1 (fr) 2011-03-08 2012-09-13 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
EP2683702B1 (fr) 2011-03-08 2014-12-24 Sanofi Nouveaux dérivés de phényle-oxathiazine substitués, leur procédé de fabrication, médicament contenant ces liaisons et son utilisation
EP2683701B1 (fr) 2011-03-08 2014-12-24 Sanofi Dérivés d'oxathiazine substitués par des groupes de benzyle-méthyles ou d'hétéro-méthyles, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012170561A1 (fr) * 2011-06-06 2012-12-13 The Scripps Research Institute (T.S.R.I.) Modulateurs n-benzylindole du pparg
WO2012170554A1 (fr) 2011-06-06 2012-12-13 Theodore Mark Kamenecka Modulateurs n-biphénylméthylindole de pparg
US9309227B2 (en) 2011-11-22 2016-04-12 The Scripps Research Institute N-biphenylmethylbenzimidazole modulators of PPARG
WO2013085954A1 (fr) 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv Dérivés de pipéridinyl-carboxamide substitué utiles en tant qu'inhibiteurs de scd 1
US9102669B2 (en) 2011-12-06 2015-08-11 Janssen Pharmaceutica Nv Substituted piperidinyl-pyridazinyl derivatives useful as SCD 1 inhibitors
MX2014013752A (es) * 2012-05-11 2014-12-08 Abbvie Inc Inhibidores de nampt.
ES2664782T3 (es) * 2012-11-05 2018-04-23 Nantbio, Inc Derivados que contienen sulfonamida cíclica como inhibidores de la ruta de señalización de hedgehog
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
WO2014134391A1 (fr) 2013-02-28 2014-09-04 Bristol-Myers Squibb Company Dérivés de phénylpyrazole en tant que puissants inhibiteurs de rock1 et rock2
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ME03518B (fr) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Combinaisons comprenant des modulateurs allostériques positifs de sous-type 2 de récepteurs glutamatergiques métabotropes et leur utilisation
SI3096790T1 (sl) 2014-01-21 2019-11-29 Janssen Pharmaceutica Nv Kombinacije, ki vsebujejo pozitivne aleostrične modulatorje ali ortosterične agoniste metabotropnega glutamatergičnega receptorja podtipa 2 in njihova uporaba
WO2015161108A1 (fr) 2014-04-16 2015-10-22 The Scripps Research Institute Modulateurs de pparg pour le traitement de l'ostéoporose
SG11201610195UA (en) * 2014-07-16 2017-01-27 Novogen ltd Functionalised and substituted indoles as anti-cancer agents
CN107108581B (zh) * 2014-08-21 2020-06-23 百时美施贵宝公司 作为强效rock抑制剂的回接苯甲酰胺衍生物
WO2016040498A1 (fr) * 2014-09-10 2016-03-17 Epizyme, Inc. Composés carboxamides isoxazoles
US10189775B2 (en) * 2015-08-28 2019-01-29 Glenmark Pharmaceuticals S.A. Carbocyclic compounds as ROR gamma modulators
BR112018015389B1 (pt) 2016-03-17 2023-12-19 F. Hoffmann-La Roche Ag Derivado de 5-etil-4-metil-pirazol-3-carboxamida, seu processo de fabricação, preparação farmacêutica oral e uso
CN108815167B (zh) * 2017-05-24 2021-04-13 四川晶华生物科技有限公司 一种化合物在制备治疗肿瘤的药物中的用途
TW202136238A (zh) * 2020-01-06 2021-10-01 大陸商廣東東陽光藥業有限公司 RORγt抑制劑及其製備方法和用途
WO2022150962A1 (fr) * 2021-01-12 2022-07-21 Westlake Pharmaceutical (Hangzhou) Co., Ltd. Inhibiteurs de protéase, leur préparation et leurs utilisations
CN115160269A (zh) * 2021-04-02 2022-10-11 北京大学 芳甲酰胺类衍生物作为nmdar的正性变构调节剂
WO2023141432A2 (fr) 2022-01-18 2023-07-27 Maze Therapeutics, Inc. Inhibiteurs d'apol1 et méthodes d'utilisation

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013502A1 (fr) * 1994-10-26 1996-05-09 Pharmacia & Upjohn Company Composes antimicrobiens de phenyloxazolidinone
WO1999024406A1 (fr) * 1997-11-07 1999-05-20 Schering Corporation Phenyl-alkyl-imidazoles utilises comme antagonistes du recepteur h¿3?
WO2000061569A1 (fr) * 1999-04-09 2000-10-19 Astrazeneca Ab Derives d'adamantane
WO2000071529A1 (fr) * 1999-05-25 2000-11-30 Astrazeneca Ab Composes phenyle substitues a activite immunosuppresseur et compositions pharmaceutiques
WO2002006232A1 (fr) * 2000-07-17 2002-01-24 Wyeth Agonistes du recepteur beta-3 adrenergique d'aminephenyle cyclique
WO2002006278A1 (fr) * 2000-07-17 2002-01-24 Ranbaxy Laboratories Limited Derives d'oxazolidinone utilises en tant qu'antimicrobiens
EP1176140A1 (fr) * 1999-02-10 2002-01-30 Mitsubishi Pharma Corporation Composes amide et leur utilisation medicinale
WO2002010146A1 (fr) * 2000-07-31 2002-02-07 Smithkline Beecham P.L.C. Composes du carboxamide et leur utilisation comme antagonistes d'un recepteur 11cby humain
WO2002020501A2 (fr) * 2000-09-04 2002-03-14 Janssen Pharmaceutica N.V. Polyarylcarboxamides utilises comme agents hypolipidemiants
WO2002042271A2 (fr) * 2000-11-21 2002-05-30 Janssen Pharmaceutica N.V. Biphenylcarboxamides utiles comme hypolipidemiants
JP2002338537A (ja) * 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
WO2002098871A1 (fr) * 2001-06-01 2002-12-12 Tanabe Seiyaku Co., Ltd. Phenylcarboxamides et procede de preparation correspondant
WO2002099388A2 (fr) * 2001-06-07 2002-12-12 Merck & Co., Inc. Benzodiazepines antagonistes de bradykinine
WO2002098839A1 (fr) * 2001-06-01 2002-12-12 Tanabe Seiyaku Co., Ltd. Biphenylcarboxamides et procede de preparation de ceux-ci
WO2003091256A1 (fr) * 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Derive de pyrazolo[1,5-a]pyrimidine et inhibiteur de la nad(p)h oxydase contenant ledit derive

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
HUP9902056A3 (en) 1996-01-17 2002-02-28 Novo Nordisk As Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
PT958296E (pt) 1996-12-31 2003-11-28 Reddys Lab Ltd Dr Compostos heterociclicos processo para a sua preparacao composicoes farmaceuticas contendo-os e sua utilizacao no tratamento da diabetes e doencas relacionadas
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
WO1999003861A1 (fr) 1997-07-16 1999-01-28 Novo Nordisk A/S Derives de 1,2,4-thiadiazine fusionnee, leur preparation et utilisation
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
EP1140087A4 (fr) 1998-12-18 2002-04-03 Du Pont Pharm Co N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
JP2002542245A (ja) 1999-04-16 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 置換イミダゾール、それらの製造および使用
CA2371271A1 (fr) 1999-04-30 2000-11-09 Neurogen Corporation Derives 9h-pyrimido[4,5-b]indoles: ligands specifiques de crf1
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
EP1194146B1 (fr) 1999-06-18 2006-07-19 Merck & Co., Inc. Derives d'arylthiazolidinedione et d'aryloxazolidinedione
AU768310B2 (en) 1999-07-29 2003-12-04 Eli Lilly And Company Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
AU774071B2 (en) 1999-09-01 2004-06-17 Sanofi-Aventis Deutschland Gmbh Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
ATE369337T1 (de) 2000-04-28 2007-08-15 Asahi Kasei Pharma Corp Neue bizyklische verbindungen
CA2408486A1 (fr) 2000-05-11 2001-11-15 Bristol-Myers Squibb Company Analogues de tetrahydroisoquinoline servant de secretagogues d'hormones de croissance
WO2001091752A1 (fr) 2000-05-30 2001-12-06 Merck & Co., Inc. Agonistes du recepteur de la melanocortine
DE10142734A1 (de) 2001-08-31 2003-03-27 Aventis Pharma Gmbh Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP2004175739A (ja) * 2002-11-28 2004-06-24 Tanabe Seiyaku Co Ltd 医薬組成物

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996013502A1 (fr) * 1994-10-26 1996-05-09 Pharmacia & Upjohn Company Composes antimicrobiens de phenyloxazolidinone
WO1999024406A1 (fr) * 1997-11-07 1999-05-20 Schering Corporation Phenyl-alkyl-imidazoles utilises comme antagonistes du recepteur h¿3?
EP1176140A1 (fr) * 1999-02-10 2002-01-30 Mitsubishi Pharma Corporation Composes amide et leur utilisation medicinale
WO2000061569A1 (fr) * 1999-04-09 2000-10-19 Astrazeneca Ab Derives d'adamantane
WO2000071529A1 (fr) * 1999-05-25 2000-11-30 Astrazeneca Ab Composes phenyle substitues a activite immunosuppresseur et compositions pharmaceutiques
WO2002006232A1 (fr) * 2000-07-17 2002-01-24 Wyeth Agonistes du recepteur beta-3 adrenergique d'aminephenyle cyclique
WO2002006278A1 (fr) * 2000-07-17 2002-01-24 Ranbaxy Laboratories Limited Derives d'oxazolidinone utilises en tant qu'antimicrobiens
WO2002010146A1 (fr) * 2000-07-31 2002-02-07 Smithkline Beecham P.L.C. Composes du carboxamide et leur utilisation comme antagonistes d'un recepteur 11cby humain
WO2002020501A2 (fr) * 2000-09-04 2002-03-14 Janssen Pharmaceutica N.V. Polyarylcarboxamides utilises comme agents hypolipidemiants
WO2002042271A2 (fr) * 2000-11-21 2002-05-30 Janssen Pharmaceutica N.V. Biphenylcarboxamides utiles comme hypolipidemiants
JP2002338537A (ja) * 2001-05-16 2002-11-27 Mitsubishi Pharma Corp アミド化合物およびその医薬用途
WO2004002948A1 (fr) * 2001-05-16 2004-01-08 Mitsubishi Pharma Corporation Compose amide et utilisation medicinale de ce compose
WO2002098871A1 (fr) * 2001-06-01 2002-12-12 Tanabe Seiyaku Co., Ltd. Phenylcarboxamides et procede de preparation correspondant
WO2002098839A1 (fr) * 2001-06-01 2002-12-12 Tanabe Seiyaku Co., Ltd. Biphenylcarboxamides et procede de preparation de ceux-ci
WO2002099388A2 (fr) * 2001-06-07 2002-12-12 Merck & Co., Inc. Benzodiazepines antagonistes de bradykinine
WO2003091256A1 (fr) * 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Derive de pyrazolo[1,5-a]pyrimidine et inhibiteur de la nad(p)h oxydase contenant ledit derive

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ANNAKA, MASAYUKI ET AL: "Preparation of biphenylcarboxamides as apolipoprotein B secretion inhibitors and hypolipemics", XP002301820, retrieved from STN Database accession no. 2002:946251 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ANNAKA, MASAYUKI ET AL: "Preparation of phenylcarboxamides with activity of suppressing secretion of apolipoprotein B", XP002283877, retrieved from STN Database accession no. 2002:946281 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NAITO, YOICHIRO ET AL: "Preparation of N-[(hydroxypiperidinyl)phenyl]benzamides as pharmaceuticals for treatment of atopic dermatitis, asthma, and allergic rhinitis", XP002301821, retrieved from STN Database accession no. 2002:900790 *
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SENO, KAORU ET AL: "Preparation of pyrazolo[1,5-a]pyrimidine derivatives as NAD(P)H oxidase inhibitors", XP002301822, retrieved from STN Database accession no. 2003:875291 *
WOOD, MICHAEL R. ET AL: "Benzodiazepines as Potent and Selective Bradykinin B1 Antagonists", JOURNAL OF MEDICINAL CHEMISTRY , 46(10), 1803-1806 CODEN: JMCMAR; ISSN: 0022-2623, 2003, XP002301819 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266834B2 (en) 2006-03-15 2016-02-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US8841323B2 (en) 2006-03-15 2014-09-23 Janssen Pharmaceuticals, Inc. 1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
US8906939B2 (en) 2007-03-07 2014-12-09 Janssen Pharmaceuticals, Inc. 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
US8748621B2 (en) 2007-09-14 2014-06-10 Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
US9132122B2 (en) 2007-09-14 2015-09-15 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
US8785486B2 (en) 2007-11-14 2014-07-22 Janssen Pharmaceuticals, Inc. Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US9085577B2 (en) 2009-05-12 2015-07-21 Janssen Pharmaceuticals, Inc. 7-aryl-1,2,4-triazolo[4,3-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8937060B2 (en) 2009-05-12 2015-01-20 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US9226930B2 (en) 2009-05-12 2016-01-05 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
US8716480B2 (en) 2009-05-12 2014-05-06 Janssen Pharmaceuticals, Inc. 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors

Also Published As

Publication number Publication date
CN100506792C (zh) 2009-07-01
NO20054220L (no) 2005-10-28
AR044496A1 (es) 2005-09-14
MXPA05008449A (es) 2006-05-25
PL378065A1 (pl) 2006-02-20
CO5690548A2 (es) 2006-10-31
OA13027A (en) 2006-11-10
NZ541823A (en) 2009-01-31
UY28186A1 (es) 2004-09-30
PE20040952A1 (es) 2005-02-08
KR20050101215A (ko) 2005-10-20
HRP20050710A2 (en) 2006-07-31
PA8595901A1 (es) 2004-09-16
EP1597228A2 (fr) 2005-11-23
DE10306250A1 (de) 2004-09-09
BRPI0407504A (pt) 2006-02-14
AU2004212145B2 (en) 2010-06-17
ZA200506369B (en) 2006-07-26
RU2005128551A (ru) 2006-02-10
JP2006517563A (ja) 2006-07-27
TW200510297A (en) 2005-03-16
MA27735A1 (fr) 2006-02-01
NO20054220D0 (no) 2005-09-12
WO2004072025A2 (fr) 2004-08-26
CN1774418A (zh) 2006-05-17
RS20050666A (en) 2007-12-31
CA2516118A1 (fr) 2004-08-26
UA86760C2 (ru) 2009-05-25
ECSP055967A (es) 2006-01-16
TNSN05194A1 (en) 2007-06-11
MY139102A (en) 2009-08-28
AU2004212145A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
WO2004072025A3 (fr) N-arylheterocycles substitues, procede de production et utilisation de ces derniers en tant que medicaments
WO2003084922A8 (fr) Derives d'acyl-4-carboxyphenyluree, procedes de production de ces derives et leur utilisation
MXPA03009840A (es) Derivados de fenilurea sustituidos con carboxamida y metodo para la produccion de los mismos como farmacos.
JO2707B1 (ar) مشتقات ثيوفين جليكوسايد جديدة, طرق تحضيرها, والادوية المحتوية على هذه المركبات واستخدامها
WO2005116003A3 (fr) Derives de dioxyde de benzisothiazole-oxazole substitues, procede de production desdits derives et leur utilisation
WO2006099943A8 (fr) 8-n-benzimidazoles a substitution amide, leur procede de production, et leur utilisation en tant que medicaments
WO2006059149A8 (fr) Derives de l'arylsulfonylnaphtalene utilises en tant qu'antagonistes de 5ht2a
WO2006005741A3 (fr) Composes organiques
TNSN06409A1 (en) Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof
WO2004098494A3 (fr) Composés, compositions et procédés
WO2005037198A3 (fr) Preparation d'azabenzimidazoles 1,7-disubstitues comme inhibiteurs de kinases
RS20060250A (en) 1-amino-2-oxy-substituted tetrahydronaphtalene derivatives, method for the production thereof, and their use as antiphlogistics
RS20050564A (en) Substituted hexahydropyrazino (1,2-a)pyrimidin-4,7-dion derivatives, method for the production and use thereof as medicaments
PL1660449T3 (pl) Pochodne aminopropanolu
IL165558A0 (en) N-benzoylureidocinnamate derivatives method for production and use thereof
IL176915A0 (en) Cycloalkyl substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
WO2004032908A3 (fr) Methode d'inhibition de l'angiogenese
WO2004087700A8 (fr) Derives du benzenesulfonamide, leur procede de preparation et leur utilisation de la douleur
RS88704A (en) Acyl-3-carboxyphenylurea derivatives, method for production and use thereof
IL166057A0 (en) Urea-substituted and urethane-substituted acylureas methods for the production thereof and their useas medicaments
WO2008023003A8 (fr) Associations médicamenteuses destinées au traitement de maladies des voies respiratoires
TNSN06233A1 (en) 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
WO2006078887A3 (fr) Derives de methylphenidate et leurs utilisations
WO2003076429A3 (fr) Nouveaux dérivés d'azépane
WO2006099940A8 (fr) 8-pyrrolidino-benzimidazoles bicycliques substitues, leur procede de production, et leur utilisation en tant que medicaments

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-2005/0666

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005/06369

Country of ref document: ZA

Ref document number: PA/a/2005/008449

Country of ref document: MX

Ref document number: 200506369

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 170249

Country of ref document: IL

Ref document number: 05079788

Country of ref document: CO

Ref document number: 1902/CHENP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 378065

Country of ref document: PL

Ref document number: P20050710A

Country of ref document: HR

Ref document number: 1020057014989

Country of ref document: KR

Ref document number: 2004212145

Country of ref document: AU

Ref document number: 2006501827

Country of ref document: JP

Ref document number: KE

WWE Wipo information: entry into national phase

Ref document number: DZP2005000289

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2516118

Country of ref document: CA

Ref document number: 1-2005-501496

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 541823

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2004212145

Country of ref document: AU

Date of ref document: 20040213

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004212145

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004710808

Country of ref document: EP

Ref document number: 2005128551

Country of ref document: RU

Ref document number: 1200501280

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 20048098606

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020057014989

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004710808

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0407504

Country of ref document: BR

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)